SOC Chemotherapy

Phase 2Small molecule

KKathy Miller

SOC Chemotherapy is one of 46 small molecule programs targeting Metastatic Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Breast CancerRecruiting

Metastatic Breast CancerPhase 2

Recruiting

Competition

Competitive Landscape

48 competitors in Metastatic Breast Cancer

#DrugCompanyPhaseTrials

Kisqali

Novartis

Approved

6 2

Femara

Novartis

Approved

2 3

Nolvadex

AstraZeneca

Approved

1 4

Faslodex

FFresenius Kabi USA, LLC

Approved

8 5

Arimidex

IIstituto Clinico Humanitas

Approved

2 6

Zoladex

TTerSera Therapeutics LLC

Approved

1 7

Ibrance

Pfizer

Phase 3

6 8

Fotivda

Roche

Phase 3

2 9

Taxol

Teva

Phase 3

1 10

Abraxane

Bristol-Myers Squibb

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Metastatic Breast Cancer

NCT05846789

Q2 2031

PreclinicalRecruiting

Solid Tumor

NCT06750185

Q1 2033

Phase 3Not yet recruiting

Breast Cancer

NCT07178730

Clinical

Trials by Indication[1]

Metastatic PDAC1 trial

MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC

Terminated·LLudwig-Maximilians - University of Munich·Phase 2·NCT05114213·9 enrolled

Solid Tumor1 trial

A Phase I/II, First-in-human, Open-label Trial of the Safety, Efficacy, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Participants With Advanced Solid Tumors

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT06750185·248 enrolled

Metastatic Breast Cancer1 trial

A Pragmatic Phase II Trial of Chemotherapy +/- Tocilizumab for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

Recruiting·KKathy Miller·Phase 2·NCT05846789·168 enrolled

Breast Cancer1 trial

NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

Not yet recruiting·WWest German Study Group·Phase 3·NCT07178730·765 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for SOC Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SOC Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SOC Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kathy Miller company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKathy Miller

SOC Chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2031

Q1 2033

Trials by Indication[1]

Metastatic PDAC1 trial

Solid Tumor1 trial

Metastatic Breast Cancer1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News